LitAlert ~~ GeneLit.com

    • Evaluating the role of NTHL1 p.Q90* allele in inherited breast cancer predisposition.
    • Kumpula T, Tervasmäki A, Mantere T, Koivuluoma S, Huilaja L, Tasanen K, Winqvist R, de Voer RM, Pylkäs K.
    • Mol Genet Genomic Med. 2020 Sep 19:e1493. doi: 10.1002/mgg3.1493. Epub ahead of print
    • Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    • Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K.
    • Gynecol Oncol. 2020 Sep 18:S0090-8258(20)33814-2. doi: 10.1016/j.ygyno.2020.08.013. Epub ahead of print.
    • COH outcomes in breast cancer patients for fertility preservation: a comparison with the expected response by age.
    • Malacarne E, Devesa M, Martinez F, Rodriguez I, Coroleu B.
    • J Assist Reprod Genet. 2020 Sep 18. doi: 10.1007/s10815-020-01944-x. Epub ahead of print.
    • Predicted chemotherapy benefit for breast cancer patients with germline pathogenic variants in cancer susceptibility genes.
    • Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Katz SJ.
    • JNCI Cancer Spectr. 2020 Sep 18; pkaa083. doi: 10.1093/jncics/pkaa083. eCollection 2020 Sep.
    • The Impact of the Number of Tests Presented and a Provider Recommendation on Decisions about Genetic Testing for Cancer Risk.
    • Schwartz MLB, Klein WMP, Erby LAH, Smith CH, Roter DL.
    • Patient Educ Couns. 2020 Sep 18:S0738-3991(20)305188. doi: 10.1016/j.pec.2020.09.020. Epub ahead of print.
    • Electronic health records contain dispersed risk factor information that could be used to prevent breast and ovarian cancer.
    • Payne TH, Zhao LP, Le C, Wilcox P, Yi T, Hinshaw J, Hussey D, Kostrinsky-Thomas A, Hale M, Brimm J, Hisama FM.
    • J Am Med Inform Assoc. 2020 Sep 17:ocaa152. doi: 10.1093/jamia/ocaa152. Epub ahead of print.
    • Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.
    • Green RF, Kumerow MT, Rodriguez JL, Addie S, Beachy SH, Senier L.
    • Public Health Genomics. 2020 Sep 17:1-12. doi: 10.1159/000510336. Epub ahead of print.
    • Robot-assisted Nipple-sparing Mastectomy with Immediate Breast Reconstruction: An Initial Experience of the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG).
    • Ryu JM, Kim JY, Choi HJ, Ko BS, Kim J, Cho J, Lee MH, Choi JE, Kim JH, Lee J, Jung SM, Shin HJ, Lee J, Park HS.
    • Ann Surg. 2020 Sep 15. doi: 10.1097/SLA.0000000000004492. Epub ahead of print.
    • Nouvelle AMM : olaparib — cancer du pancréas avec mutation germinale de BRCA [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    • Hilmi M, Neuzillet C.
    • Bull Cancer. 2020 Sep 14:S0007-4551(20)30324-6. French. doi: 10.1016/j.bulcan.2020.06.009. Epub ahead of print.
    • Letter, News, [Article in French]
    • Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    • Gou R, Dong H, Lin B.
    • Life Sci. 2020 Sep 14:118434. doi: 10.1016/j.lfs.2020.118434. Epub ahead of print.
    • Examining information-seeking behavior in genetic testing for cancer predisposition: a qualitative interview study.
    • Zimmermann BM, Fanderl J, Koné I, Rabaglio M, Bürkic N, Shaw D, Elgera B.
    • Patient Educ Couns. 2020 Sep 17:S0738-3991(20)305176. doi: 10.1016/j.pec.2020.09.019. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
    • Olafsdottir EJ, Borg A, Jensen MB, Gerdes AM, Johansson ALV, Barkardottir RB, Johannsson OT, Ejlertsen B, Sønderstrup IMH, Hovig E, Lænkholm AV, Hansen TVO, Olafsdottir GH, Rossing M, Jonasson JG, Sigurdsson S, Loman N, Nilsson MP, Narod SA, Tryggvadottir L.
    • Br J Cancer. 2020 Sep 17. doi: 10.1038/s41416-020-01056-4. Epub ahead of print.
    • PARP inhibition in treatment of pancreatic cancer.
    • Hammel P, Zhang C, Matile J, Colle E, Hadj-Naceur I, Gagaille MP, Bouattour M, Cros J, de Mestier L, Lamuraglia M.
    • Expert Rev Anticancer Ther. 2020 Sep 16:1-7. doi: 10.1080/14737140.2020.1820330. Epub ahead of print.
    • Review
    • A pilot randomized trial of an educational intervention to increase genetic counseling and genetic testing among Latina breast cancer survivors.
    • Conley CC, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Burgos C, Ricker C, Kim J, Graves KD, Ashing KT, Quinn GP, Soliman H, Vadaparampil ST.
    • J Genet Couns. 2020 Sep 16. doi: 10.1002/jgc4.1324. Epub ahead of print.
    • A shared genetic contribution to breast cancer and schizophrenia.
    • Lu D, Song J, Lu Y, Fall K, Chen X, Fang F, Landén M, Hultman CM, Czene K, Sullivan P, Tamimi RM, Valdimarsdóttir UA.
    • Nat Commun. 2020 Sep 15;11(1):4637. doi: 10.1038/s41467-020-18492-8.
    • A Survey of Rare Epigenetic Variation in 23,116 Human Genomes Identifies Disease-Relevant Epivariations and CGG Expansions.
    • Garg P, Jadhav B, Rodriguez OL, Patel N, Martin-Trujillo A, Jain M, Metsu S, Olsen H, Paten B, Ritz B, Kooy RF, Gecz J, Sharp AJ.
    • Am J Hum Genet. 2020 Sep 8:S0002-9297(20)30288-3. doi: 10.1016/j.ajhg.2020.08.019. Epub ahead of print.
    • A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.
    • Inuzuka M, Watanabe C, Yokoyama S, Kuwayama T, Akashi-Tanaka S, Arai M, Nakamura S; Registration Committee of the Japanese HBOC consortium.
    • Clin Breast Cancer. 2020 Aug 20:S1526-8209(20)30209-3. doi: 10.1016/j.clbc.2020.08.004. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status.
    • Olafsdottir EJ, Borg A, Jensen MB, Gerdes AM, Johansson ALV, Barkardottir RB, Johannsson OT, Ejlertsen B, Heeholm Sønderstrup IM, Hovig E, Lænkholm AV, van Overeem Hansen T, Olafsdottir GH, Rossing M, Jonasson JG, Sigurdsson S, Loman N, Nilsson MP, Narod SA, Tryggvadottir L.
    • Br J Cancer. 2020 Sep 17. doi: 10.1038/s41416-020-01056-4. [Epub ahead of print]
    • A pilot randomized trial of an educational intervention to increase genetic counseling and genetic testing among Latina breast cancer survivors.
    • Conley CC, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Burgos C, Ricker C, Kim J, Graves KD, Ashing KT, Quinn GP, Soliman H, Vadaparampil ST.
    • J Genet Couns. 2020 Sep 16. doi: 10.1002/jgc4.1324. Epub ahead of print.
    • A shared genetic contribution to breast cancer and schizophrenia.
    • Lu D, Song J, Lu Y, Fall K, Chen X, Fang F, Landén M, Hultman CM, Czene K, Sullivan P, Tamimi RM, Valdimarsdóttir UA.
    • Nat Commun. 2020 Sep 15;11(1):4637. doi: 10.1038/s41467-020-18492-8.
    • A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.
    • Inuzuka M, Watanabe C, Yokoyama S, Kuwayama T, Akashi-Tanaka S, Arai M, Nakamura S; Registration Committee of the Japanese HBOC consortium.
    • Clin Breast Cancer. 2020 Aug 20:S1526-8209(20)30209-3. doi: 10.1016/j.clbc.2020.08.004. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Intrafamilial communication of hereditary breast and ovarian cancer genetic information in Italian women: towards a personalised approach.
    • Di Pietro ML, Zaçe D, Orfino A, Di Raimo FR, Poscia A, de Matteis E, Turchetti D, Godino L, Beronazzi B, Franiuk M, Bruzzone C, Varesco L, Lucci-Cordisco E, Genuardi M.
    • Eur J Hum Genet. 2020 Sep 14. doi: 10.1038/s41431-020-00723-7. Epub ahead of print.
    • The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
    • Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL.
    • Int J Gynecol Cancer. 2020 Sep 14:ijgc-2020-001789. doi: 10.1136/ijgc-2020-001789. Epub ahead of print.
    • Review
    • BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
    • Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, Grandori C.
    • EBioMedicine. 2020 Sep 11;60:102988. doi: 10.1016/j.ebiom.2020.102988. Epub ahead of print.
    • What is the role of PARP inhibitors in pancreatic cancer?
    • Halder R, T Shroff R.
    • Expert Rev Anticancer Ther. 2020 Sep 11:1-6. doi: 10.1080/14737140.2020.1816174. Epub ahead of print.
    • Integrative Review of Reproductive Decision Making of Women Who Are BRCA Positive.
    • Skrovanek E, Dunbar-Jacob J, Dunwoody C, Wesmiller S.
    • J Obstet Gynecol Neonatal Nurs. 2020 Sep 11:S0884-2175(20)30117-9. doi: 10.1016/j.jogn.2020.07.006. Epub ahead of print.
    • Review
    • Splicing Enhancers at Intron-Exon Borders Participate in Acceptor Splice Sites Recognition.
    • Kovácová T, Soucek P, Hujová P, Freiberger T, Grodecká L.
    • Int J Mol Sci. 2020 Sep 8;21(18):E6553. doi: 10.3390/ijms21186553.
    • Male Breast Cancer in Togo: Imaging and Clinicopathological Findings.
    • Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G.
    • Int J Breast Cancer. 2020 Aug 31;2020:3056067. doi: 10.1155/2020/3056067.
    • Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.
    • Silva Filho ALD, Carvalho GM, Sena LC, Gomes LPG, Valério MFH, Martins RIL, Cândido EB.
    • Rev Assoc Med Bras (1992). 2020 Aug;66(8):1134-1138. doi: 10.1590/1806-9282.66.8.1134.
  • LitAlert ~~ GeneLit.com

    • What is the role of PARP inhibitors in pancreatic cancer?
    • Halder R, T Shroff R.
    • Expert Rev Anticancer Ther. 2020 Sep 11:1-6. doi: 10.1080/14737140.2020.1816174. Epub ahead of print.
    • Splicing Enhancers at Intron-Exon Borders Participate in Acceptor Splice Sites Recognition.
    • Kovácová T, Soucek P, Hujová P, Freiberger T, Grodecká L.
    • Int J Mol Sci. 2020 Sep 8;21(18):E6553. doi: 10.3390/ijms21186553.
  • LitAlert ~~ GeneLit.com

    • A microfluidic chip for rapid analysis of DNA melting curves for BRCA2 mutation screening.
    • Lin X, Nagl S.
    • Lab Chip. 2020 Sep 14. doi: 10.1039/d0lc00624f. Epub ahead of print.
    • Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?
    • Alberty-Oller JJ, Weltz S, Santos A, Pisapati K, Ru M, Weltz C, Schmidt H, Port E.
    • Ann Surg Oncol. 2020 Sep 11. doi: 10.1245/s10434-020-09123-z. Epub ahead of print.
    • BRCA1/2 Testing in Massachusetts Among Women With Private Insurance or Medicaid, 2011-2015.
    • Pace LE, Baum CF, Horvath K, Raja SC, Cohen J, Hawkins SS.
    • Med Care. 2020 Sep 10. doi: 10.1097/MLR.0000000000001405. Epub ahead of print.
    • Germline mutations and prostate cancer: is it time to change treatment algorithms?
    • Telvizian T, Mukherji D.
    • Chin Clin Oncol. 2020 Aug 27:cco-19-207. doi: 10.21037/cco-19-207. Epub ahead of print.
    • Management of early breast cancer in patients bearing germline BRCA mutations.
    • t'Kint de Roodenbeke MD, Pondé N, Buisseret L, Piccart M.
    • Semin Oncol. 2020 Aug 18:S0093-7754(20)30083-X. doi: 10.1053/j.seminoncol.2020.07.006. Epub ahead of print.
    • Review
    • Structure-based functional analysis of BRCA1 RING domain variants: Concordance of computational mutagenesis, experimental assay, and clinical data.
    • Masso M, Bansal A, Bansal A, Henderson A.
    • Biophys Chem. 2020 Aug 1;266:106442. doi: 10.1016/j.bpc.2020.106442. Epub ahead of print.
    • BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer.
    • Liu YL, Selenica P, Zhou Q, Iasonos A, Callahan M, Feit NZ, Boland J, Vazquez-Garcia I, Mandelker D, Zehir A, Burger RA, Powell DJ Jr, Friedman C, Cadoo K, Grisham R, Konner JA, O'Cearbhaill RE, Aghajanian C, Reis-Filho JS, Weigelt B, Zamarin D.
    • JCO Precis Oncol. 2020 Jun 16;4:PO.20.00069. doi: 10.1200/PO.20.00069.
  • LitAlert ~~ GeneLit.com

    • Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
    • Power R, Leavy C, Nolan C, White N, Clarke R, Cadoo KA, Gallagher DJ, Lowery MA.
    • Fam Cancer. 2020 Sep 12. doi: 10.1007/s10689-020-00205-1. [Epub ahead of print]
    • Assessment of mismatch repair deficiency in ovarian cancer.
    • Crosbie EJ, Ryan NAJ, McVey RJ, Lalloo F, Bowers N, Green K, Woodward ER, Clancy T, Bolton J, Wallace AJ, McMahon RF, Evans G.
    • J Med Genet. 2020 Sep 11:jmedgenet-2020-107270. doi: 10.1136/jmedgenet-2020-107270. Epub ahead of print.
    • Assessment of mismatch repair deficiency in ovarian cancer.
    • Crosbie EJ, Ryan NAJ, McVey RJ, Lalloo F, Bowers N, Green K, Woodward ER, Clancy T, Bolton J, Wallace AJ, McMahon RF, Evans G.
    • J Med Genet. 2020 Sep 11:jmedgenet-2020-107270. doi: 10.1136/jmedgenet-2020-107270. Epub ahead of print.